



UNIVERSITÀ POLITECNICA DELLE MARCHE
Repository ISTITUZIONALE

Transcriptional and cellular effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in experimentally exposed mussels, *Mytilus galloprovincialis*

This is the peer reviewed version of the following article:

Original

Transcriptional and cellular effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in experimentally exposed mussels, *Mytilus galloprovincialis* / Mezzelani, Marica; Gorbi, Stefania; Fattorini, Daniele; D'Errico, Giuseppe; Benedetti, Maura; Milan, Massimo; Bargelloni, Luca; Regoli, Francesco. - In: AQUATIC TOXICOLOGY. - ISSN 0166-445X. - 180:1(2016), pp. 306-319. [10.1016/j.aquatox.2016.10.006]

Availability:

This version is available at: 11566/239585 since: 2022-06-01T13:00:50Z

Publisher:

Published

DOI:10.1016/j.aquatox.2016.10.006

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. The use of copyrighted works requires the consent of the rights' holder (author or publisher). Works made available under a Creative Commons license or a Publisher's custom-made license can be used according to the terms and conditions contained therein. See editor's website for further information and terms and conditions.

This item was downloaded from IRIS Università Politecnica delle Marche (<https://iris.univpm.it>). When citing, please refer to the published version.

note finali coverpage

(Article begins on next page)

1 **Transcriptional and cellular effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in**
2 **experimentally exposed mussels, *Mytilus galloprovincialis***

3
4 3 *M. Mezzelani^a, S. Gorbi^a, D. Fattorini^a, G. d'Errico^a, M. Benedetti^a, M. Milan^b, L. Bargelloni^b, F.*
5
6 4 *Regoli^{ac*}*
7

8 5
9
10 6 ^a Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA), Università Politecnica delle Marche,
11
12 7 Ancona, Italy

13 8 ^b Dipartimento di Biomedicina Comparata e Alimentazione (BCA), Università di Padova, Italy

14
15 9
16 10 ^c CoNISMa, Consorzio Interuniversitario per le Scienze del Mare, Roma, Italy
17

18 11

19

20

21 12

22

23

24 13

25

26 14

27

28

29 15

30

31

32 16

33

34 17

35

36

37 18

38

39

40 19

41

42

43 20

44

45 21

46

47

48 22

49

50

51 23

52

53 24

54

55 25

56

57 26

58

59 27

60

61

62

63

64

65

* Corresponding Author: Prof. Francesco Regoli

Dipartimento di Scienze della Vita e dell'Ambiente (DiSVA),

Università Politecnica delle Marche,

via Breccie Bianche 60131, Ancona, Italy

e-mail: f.regoli@univpm.it

28 **ABSTRACT**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The aim of the present investigation was to provide new insights on accumulation and possible adverse effects of various non-steroidal anti-inflammatory drugs (NSAIDs) in mussels, *Mytilus galloprovincialis*, exposed to an environmentally realistic concentration (0.5 µg/L) of individual compounds, Acetaminophen (AMP), Diclofenac (DIC), Ibuprofen (IBU), Ketoprofen (KET) or Nimesulide (NIM). The measurement of drugs in mussels tissues was integrated with both functional alterations at cellular level and transcriptomic responses. Results indicated the capability of mussels to accumulate DIC and NIM, while AMP, IBU and KET were always below detection limit. A large panel of ecotoxicological biomarkers revealed the early onset of alterations induced by tested NSAIDs on immunological responses, lipid metabolism and DNA integrity. The gene transcription analysis through DNA microarrays, supported cellular biomarker results, with clear modulation of a large number of genes involved in the arachidonic acid and lipid metabolism, immune responses, cell cycle and DNA repair. The overall results indicated an ecotoxicological concern for pharmaceuticals in *M. galloprovincialis*, with transcriptional responses appearing as sensitive exposure biomarkers at low levels of exposure: such changes, however, are not always paralleled by corresponding functional effects, suggesting caution when interpreting observed effects in terms of perturbed cellular pathways. Fascinating similarities can also be proposed in the mode of action of NSAIDs between bivalves and vertebrates species.

Keywords: Non-Steroidal Anti-Inflammatory Drugs, marine mussels, bioaccumulation, biomarkers, DNA-microarray

1. Introduction

Pharmaceutical compounds are increasingly documented as emerging contaminants in aquatic environments due to their massive use and the often limited removal by waste water treatment plants (Lolić et al., 2015; Petrie et al., 2014). Their ubiquitous presence in aquatic ecosystems and the evidence that these molecules are bioactive at low concentrations, raised the awareness of both scientific community and legislative authorities (Boxall et al., 2012; Santos et al., 2010). Effects of pharmaceuticals have been extensively characterized in humans and mammals, and it has been speculated whether they might affect non-target aquatic organisms with analogous mechanisms of action (MOA) on various species, tissues, cells, or biomolecules (Bebiano and Gonzalez-Rey, 2015; Boxall et al., 2012; Fent et al., 2006; Milan et al., 2013a). The major concern is related to the potential adverse effects on organisms permanently exposed to those compounds over their whole life cycle (Ankley et al., 2007; Fent et al., 2006).

Within the huge spectrum of environmental pharmaceuticals, non-steroidal anti-inflammatory drugs (NSAIDs) have been widely detected in aquatic ecosystems with concentrations ranging between few ng/L up to several µg/L in sewage treatment plants (STP) influents and effluents, rivers, groundwater, and coastal areas (Al Aukidy et al., 2012; Lolić et al., 2015; Pal et al., 2010). From initial studies on deleterious effects of pharmaceuticals in the environment assessed through acute toxicity tests (Santos et al., 2010), the ecotoxicological investigations have later focused on freshwater species, as those more directly exposed to compounds discharged by STP effluents into rivers (Gagné et al., 2005). For a long time, pharmaceuticals have not been considered to be harmful for oceans, due to the high dilution capacity of marine waters (Fabbri and Franzellitti, 2015). However, a recent study documented the occurrence of NSAIDs in wild populations of mussels, *Mytilus galloprovincialis*, collected in coastal areas of the Adriatic Sea (Mezzelani et al., 2016), converting this emerging issue into a potential threat also for marine ecosystems.

Investigations on pharmaceuticals in marine species are still limited, especially those addressing integrated questions on the environmental presence of these substances, their bioavailability to non-target species, and the onset of adverse effects at different levels of biological organization, i.e. from molecular alterations to organisms' health impairment. Such multidisciplinary approaches are fundamental within Environmental Risk Assessment (ERA) procedures, actually lacking for pharmaceuticals in the marine ecosystem. Mussels, *Mytilus spp.*, have been demonstrated to be suitable sentinel organisms for investigating accumulation and ecotoxicological effects of NSAIDs (Bebiano and Gonzalez-Rey, 2015; Mezzelani et al., 2016). Laboratory exposures to 25 µg/L of different compounds revealed the capability of these organisms

84 to accumulate Diclofenac (DIC), Ibuprofen (IBU) and Nimesulide (NIM), while Acetaminophen
85 (AMP) and Ketoprofen (KET) were never detectable in mussels tissues (Mezzelani et al., 2016). On
86 the other hand, all tested NSAIDs determined the clear onset of biochemical alterations, with
87 modulation of lysosomal and immune system, a direct effect on stored energy reserves, and cellular
88 alterations, potentially related to cell cycle modulation (Mezzelani et al., 2016).

89 Based on such results, the aim of the present study was to investigate whether anti-
90 inflammatory pharmaceuticals exert their ecotoxicological potential even at much lower,
91 environmentally realistic concentrations. In this respect, specimens of *M. galloprovincialis* were
92 exposed for 14 days to individual drugs, respectively AMP, DIC, IBU, KET or NIM, each dosed at
93 a concentration of 0.5 µg/L. This value is well within the range of those measured in different
94 aquatic bodies, including marine environments and the Mediterranean Sea (Table 1). In some
95 locations, detected levels were very low or even below detection limit, as it could be expected for
96 any class of anthropogenic pollutants in pristine areas. However, concentrations spanning from
97 hundreds up to thousands of ng/L were quite frequent and, worthy to note, the highest field
98 concentrations measured in the Mediterranean Sea were greater than those used in the present study
99 (200 µg/L for Acetaminophen, 1.5 µg/L for Diclofenac, 1.5 µg/L for Ibuprofen, 6 µg/L for
100 Ketoprofen).

101 Accumulation of pharmaceuticals in tissues of exposed mussels was integrated with a large
102 panel of cellular alterations such as immunological parameters, lysosomal membrane stability,
103 antioxidant defences and oxidative stress biomarkers, the onset of genotoxicity, fatty acid
104 metabolisms and neurotoxic effects. The overall results on biomarker responses were elaborated
105 within a quantitative model (SediquaSoft) which uses weighted criteria to summarize a cellular
106 hazard index, based on the number, biological relevance and magnitude of the observed effects
107 (Benedetti et al., 2012, 2014; Piva et al., 2011; Regoli et al., 2014). Measurements of functional
108 effects at cellular level were further integrated with transcriptomic analyses in mussels exposed to
109 KET and NIM, which had been previously shown to cause a similar ecotoxicological hazard at
110 cellular level, despite their opposite behaviour in bioconcentration potential (Mezzelani et al.,
111 2016). Although molecular changes are often considered to anticipate or support similar variations
112 at corresponding biochemical or cellular pathways, several post-transcriptional and modulatory
113 factors can influence links between different intracellular levels, which might be not necessarily
114 present or easy to predict (Regoli et al., 2011; Giuliani et al., 2013; Regoli and Giuliani 2014).

115 Obtained results were expected to provide new insights on the putative MOA and
116 ecotoxicological potential of NSAIDs in non-target marine organisms, thus representing an

117 additional step to support more comprehensive processes of environmental risk assessment and
118 future management decisions on this new class of environmental pollutants.

119

120 **2. Materials and methods**

121 *2.1 Experimental design*

122 Chemicals, including Acetaminophen, Diclofenac, Ibuprofen, Ketoprofen and Nimesulide,
123 were obtained from Sigma Aldrich. For each molecule a stock solution (10 mg/L in methanol) was
124 prepared and stored at room temperature, while working solutions for mussels exposures were daily
125 obtained by dilution in seawater.

126 Mussels, *M. galloprovincialis* (5 ± 1 cm shell length), were collected from a local farm
127 (Ancona, Adriatic Sea) and acclimatized for 10 days to laboratory conditions with aerated seawater,
128 at $18 \pm 1^\circ\text{C}$, salinity 37, pH 8.0 ± 0.5 and oxygen saturation $>94\%$. A total of 360 mussels were
129 randomly distributed into six 20 L glass-tanks (60 mussels per tank); the experimental design
130 included five tanks with organisms exposed to $0.5 \mu\text{g/L}$ of individual pharmaceuticals, AMP, DIC,
131 IBU, KET or NIM respectively, and a solvent control tank (CTRL) where methanol was added at
132 the same concentration used in the NSAIDs treatments (0.005%). Water was changed and all the
133 molecules re-dosed on a daily basis: for this reason, we did not measure concentrations of NSAIDs
134 in seawater, but we preferred to analyse the bioaccumulation of these pharmaceuticals in mussels
135 tissues, considering this information much more relevant to interpret and discuss observed
136 biological responses. No mortality of mussels was observed during the experiments.

137 After 14 days of exposure, 30 specimens for each treatment were dissected for chemical
138 analyses, pooled in 5 samples (each containing whole tissues of 6 organisms) and stored at -20°C .
139 Haemolymph, digestive glands and gills were rapidly removed from the remaining 30 specimens for
140 each treatment, pooled in 10 samples (each constituted by tissues of 3 specimens) frozen in liquid
141 nitrogen and maintained at -80°C for biochemical and histochemical analyses. An aliquot of
142 haemolymph was also immediately processed for lysosomal membrane stability, phagocytosis
143 activity and DNA damage; another aliquot was fixed in Carnoy's solution (3:1 methanol, acetic
144 acid) for the microscopic evaluation of granulocytes-hyalinocytes ratio and micronuclei frequency.
145 Four additional pools, each with digestive glands of three specimens, were prepared from CTRL,
146 KET and NIM groups, for DNA microarray analysis.

147

148 *2.2 Chemical analyses*

149 Analytical methods and procedures for determination of NSAIDs in mussels tissues were
150 carried out by high performance liquid chromatography (HPLC) according to previously validated

151
152
153
154
155

151 protocols (Mezzelani et al., 2016). Five replicates per group, each constituted by the whole tissues
152 of 6 specimens were used to determine levels of accumulated NSAIDs. Acetic acid 0.1%, pH=3.26
153 was used as homogenization and extraction buffer (buffer 1) for DIC, IBU, KET and NIM, while
154 ammonium phosphate 10 mM, pH=4.0 with citric acid 100 mM (buffer 2) for AMP. About 3 g of
155 wet tissues were homogenized in 5 mL of buffers at room temperature for 20 minutes. After
156 centrifugation at 4,500 xg for 30 minutes, samples were purified by Solid Phase Extraction (SPE);
157 SPE tubes were pre-conditioned with 6 mL of methanol, followed by 18 mL of ultra-pure water and
158 12 mL of the buffers: samples were then loaded and, after washing with 12 mL of ultra-pure water,
159 analytes were recovered using 3 mL of acetonitrile. Obtained samples were filtered, concentrated by
160 SpeedVac and then centrifuged again at 12,000 xg for 20 minutes.

161 Chromatographic separations of DIC, IBU, KET and NIM were performed using an Agilent
162 Infinity 1260 series system, with a C-18 Kinetex column (5 μ m, 150 mm length, 4.6 mmID,
163 Phenomenex, US). For KET and DIC a mobile phase composed by ultra-pure water (26%),
164 acetonitrile (42%) and Buffer 1 (32%) was used under isocratic condition. The signals of KET and
165 DIC were monitored and acquired with a diode array detector (DAD) at 250 nm and 276 nm
166 respectively. Separations of IBU and NIM were performed on a gradient using ultra-pure water,
167 acetonitrile and buffer 1 (from 35%:30%:35% to 0%:65%:35% for 23 minutes) on a C-18 Kinetex
168 column (5 μ m, 150 mm length, 4.6 mmID, Phenomenex, US). Detection of IBU was performed by
169 fluorimetric detector (FD) with excitation/emission wavelengths at 230/294 nm, while NIM was
170 detected using DAD monitoring at 298 nm. Separation of AMP was carried out by a C-18 Agilent
171 Eclipse Plus column (3.5 μ m, 100 mm length, 4.6 mmID) and a mobile phase composed by Buffer
172 2 (87.5%) and methanol (12.5%) under isocratic condition; signals were monitored and acquired
173 using DAD at 248 nm. Concentrations of various NSAIDs were quantified by comparison with
174 signals of pure standard solutions; due to the lack of appropriate Certified Standard Reference
175 Materials (SRMs), the reproducibility, quality control and quality assurance were assessed
176 analyzing a series of blank samples spiked with various concentrations of pure NSAIDs standards.
177 An elevated recovery yield (CV<5%, n=10, \geq 98%) was always ensured and checked; the minimum
178 measurable amounts in mussels tissues were 1 ng/g dry weight (d.w.) for AMP, DIC and NIM, and
179 0.5 ng/g (d.w.) for IBU and KET.

181 2.3 Biological responses

182 Biomarkers in tissues of exposed mussels were measured through standardized protocols
183 which included: microscopy analyses of haemocytes for lysosomal membrane stability through
184 neutral red retention time (NRRT), granulocytes/hyalinocytes ratio (G/H), phagocytosis activity;

185 histochemical quantification of lipofuscin (LIPO) and neutral lipids (NL) on digestive gland
186 cryostat sections; spectrophotometric determination of Acyl-CoA oxidase (ACOX),
187 acetylcholinesterase (AChE) in haemolymph and gills, antioxidants defences (catalase, CAT,
188 glutathione S-transferases, GST, Se-dependent and sum of Se-dependent and Se-independent
189 glutathione peroxidases, GPx H₂O₂ and GPx CHP, glutathione reductase, GR, total glutathione,
190 GSH) in digestive glands; gas-chromatographic assay of total antioxidant capacity (TOSC) toward
191 peroxy radicals (ROO·) and hydroxyl radicals (HO·) in digestive glands; electrophoretic and
192 cytogenetic analysis of DNA integrity (DNA fragmentation and micronuclei, MN) in haemocytes.
193 Detailed protocols are given in Supplementary Material 1 (SM1).

194
195

195 *2.4 Labelling, microarray hybridization and data acquisition*

196

196 Gene transcription analyses were performed using an 8x60K Agilent oligo-DNA microarray
197 platform designed within the European project REPROSEED (REsearch project to improve
198 PROduction of SEED of established and emerging bivalve species in European hatcheries). The
199 DNA microarray platform has been recently described by Avio et al. (2015). Briefly, a total of
200 50,680 different *M. galloprovincialis* contigs have been represented by 59,997 probes. Information
201 about sequencing, assembly, annotation and microarray design is summarized in Supplementary
202 Material 2 (SM2). Probe sequences and other details on the microarray platform can be found in the
203 GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) under accession number GPL18667.
204 Microarrays were synthesized in situ using the Agilent non-contact ink-jet technology including
205 default positive and negative controls.

206

206 A total of 4 pools of digestive glands, each composed by tissues of 3 individuals, was
207 analysed for gene expression analyses of CTRL, NIM and KET groups. Sample labelling and
208 hybridization were performed according to the Agilent One-Color Microarray-Based Gene
209 Expression Analysis protocol with the Low Input Quick Amp Labeling kit. Full details about
210 labelling, hybridization and data acquisition are reported in Supplementary Material 3 (SM3).

211

211 Raw gene expression data were deposited in the GEO database under accession number
212 GSE66990. Normalization procedures included quantile normalization which always outperformed
213 cyclic loess, and further adjustment by the parametric Combat in R to account for the between-
214 experiments batch effects of the oligonucleotide microarray (Johnson et al., 2007). Normalized data
215 were deposited in GEO archive under accession number GSE66990. **The functional groups of
216 analysed genes included: glycolysis/gluconeogenesis, citrate cycle, oxidative phosphorylation,
217 glycerolipid metabolism, fatty acid metabolism, drug metabolism, regulation of transcription,
218 spliceosome translation, Aminoacyl-tRNA biosynthesis, protein folding, proteolysis DNA repair,**

219

220

221

222

223

224

219 lysosome, apoptosis, cell cycle, PPAR signaling pathway, immune response and arachidonic acid
220 metabolism.

221

222 2.5 Statistical analyses

223 For chemical concentrations and biomarker responses, statistical analyses were performed
224 using the Statistica Software (Ver 6.0, StatSoft, Tulsa, OK, USA). One way analysis of variance
225 (ANOVA) was applied to test differences between various exposure groups; level of significance
226 was set at $p < 0.05$, homogeneity of variance tested by Cochran C and mathematical transformation
227 applied if necessary; post-hoc comparison (Newman-Keuls) was used to discriminate between
228 means of values ($n=5$). Descriptive multivariate statistic (principal component analyses, PCA) was
229 applied to biomarkers data for discriminating between different exposure conditions.

230 Data on biomarker responses were further elaborated within a previously developed
231 quantitative and software-assisted model (Sediqualsoft), which summarizes large data-sets of
232 heterogeneous data, providing a synthetic index of hazard: whole calculations, detailed flow-charts,
233 rationale for weights, thresholds and expert judgements have been fully given elsewhere (Benedetti
234 et al., 2014; Piva et al., 2011). Depending on species and tissue, the model assigns to each
235 biomarker a “weight” based on the toxicological relevance of analyzed endpoint, and a “threshold”
236 for changes of biological significance which consider both inductions and/or inhibitions of various
237 responses. For every analysed biomarker, the variation measured in exposed organisms is compared
238 to the threshold, then corrected for the weight of the response and the statistical significance of the
239 difference compared to controls. Depending on the magnitude of the calculated effect, each
240 biomarker response is assigned by the model to 1 of 5 classes of Effect (from Absent to Severe); the
241 calculation of the Hazard Quotient for biomarkers (HQ_{BM}) does not consider the contribution of
242 responses with an Effect lower or equal to threshold (Absent or Slight), calculates the average for
243 those with an Effect up to two-fold compared to the threshold (Moderate), and adds the summation
244 (Σ) for the responses more than 2 fold greater than the respective threshold, i.e. Major or Severe
245 (Piva et al., 2011):

246

$$HQ_{BM} = \left(\frac{\sum_{j=1}^N Effect_w(j)_{1 < Effect(j) \leq 2}}{num\ biomark_{1 < Effect(j) \leq 2}} + \sum_{k=1}^M Effect_w(k)_{Effect(j) > 2} \right)$$

247

248

249

250

251

252

253

254

255

249 According to variations measured for various biomarkers, the model summarizes the level of
250 cumulative HQ_{BM} in one of five classes of hazard for biomarkers (from Absent to Severe),
251 maintaining scientifically sound information, while also being easy to read for non-expert
252 stakeholders (Piva et al., 2011).

253 Statistical analyses of transcriptional results were performed on 45,887 out of 59,971 probes
254 with signal higher than the background in 4 out of 12 analysed samples. The TIGR Multi
255 Experiment Viewer 4.5.1 statistical software (TMeV; Saeed et al., 2003) was used to perform
256 Principal Component Analysis (PCA) and T-test statistics (Bonferroni correction for multiple
257 comparisons; p-value<0.01; 200 permutations) comparing CTRL to both KET and NIM groups.
258 The resulting T-test genes lists were then filtered and only probes with fold change (FC) > 1.5 and
259 signal higher than the background in at least one group have been considered as differentially
260 expressed genes (DEGs). A more systematic functional interpretation of differentially transcribed
261 genes was obtained through an enrichment analysis using Database for Annotation, Visualization,
262 and Integrated Discovery (DAVID) software (Huang et al., 2009). Since these databases contain
263 functional annotation data for a limited number of species, transcripts of *M. galloprovincialis* were
264 matched to *Danio rerio* Gene IDs using dedicated Blast searches performed with blastx (E-value <
265 10⁻⁵). The choice of *D. rerio* allowed the assignment of a putative homologue to a larger number of
266 *M. galloprovincialis* transcripts (Avio et al., 2015), and was previously demonstrated an useful
267 option for *Ruditapes philippinarum* functional analyses (Milan et al., 2011, 2013b). A functional
268 annotation was obtained for genes differentially expressed in each T-test pairwise comparison,
269 setting DAVID for gene count=2 and ease=0.1.

3. Results

272 Exposed mussels exhibited accumulation of DIC and NIM after 14 days, with tissue
273 concentrations of 4.75 ± 5.30 ng/g d.w. and 8.00 ± 3.99 ng/g d.w., respectively (Table 2); levels of
274 AMP, IBU and KET were always below the limit of detection (LOD).

275 Among immunological responses, lysosomal membrane stability was significantly reduced
276 in organisms exposed to IBU (Fig.1A), while granulocytes-hyalinocytes ratio and phagocytosis
277 activity increased in KET-exposed mussels (Fig. 1 B-C). Within biomarkers of cellular responses, a
278 significant accumulation of lipofuscin in tertiary lysosomes was observed after exposures to DIC
279 and NIM (Fig. 1D), and the neutral lipids content was lowered by all NSAIDs (Fig. 1E). No
280 significant variations were measured for acyl-CoA oxidase and AChE in gills of exposed mussels
281 (Fig. 1 F-G), but the latter activity was reduced in haemolymph after treatment with NIM (Fig. 1H).

282 Results on antioxidant defences and total oxyradical scavenging capacity are shown in
283 Figure 2. Activities of catalase, glutathione S-transferases, glutathione peroxidases, glutathione
284 reductase and levels of total glutathione showed only a few and not statistically significant
285 variations between different exposure conditions (Fig. 2 A-F): such limited prooxidant effects were
286 further supported by the lack of variations on the total oxyradical scavenging capacity toward both
287 peroxy (ROO•) and hydroxyl (•OH) radicals (Fig. 2 G-H). On the other hand, slight genotoxic
288 effects were measured in terms of significant enhancement of DNA strand breaks for KET exposed
289 organisms (Fig. 3A), and of micronuclei frequency after treatments with DIC, KET and NIM (Fig.
290 3B).

291 The principal component analysis (PCA) on the whole set of biomarkers produced a two
292 dimensional pattern explaining 68.29% of the total variance. The plot score indicated a clear
293 separation between control organisms (CTRL) and those exposed to DIC, KET and NIM (Fig.4).
294 The parameters determining the separation along to the PC1 axis were those related to
295 immunological alterations (granulocytes-hyalinocytes ratio, phagocytosis activity), antioxidant
296 parameters (catalase, glutathione peroxidases, total oxyradical scavenging capacity toward peroxy
297 radicals) and genotoxic effects (micronuclei frequency and DNA fragmentation); accumulation of
298 lipofuscin, acetylcholinesterase in haemolymph, glutathione S-transferases and total glutathione
299 determined the separation of the groups along to the PC2 axis. The quantitative elaboration of these
300 data based on the magnitude of variations observed for various biomarkers, their statistical
301 significance and the toxicological relevance of each biological endpoint, summarized the hazard
302 associated to biomarker responses as “Moderate” for organisms exposed to KET, “Slight” for AMP,
303 DIC, IBU and NIM (Table 3).

304 Compared to such functional effects, pairwise comparisons of gene expression data revealed
305 a total of 1,154 and 1,516 DEGs (T-test, $p < 0,01$; 200 permutations; $FC > 1.5$) in response to KET
306 and NIM exposures, with 415 transcripts commonly up- or down-regulated in both comparisons
307 (Fig. 5). Principal Component Analysis (PCA) was performed on DNA microarray data considering
308 the entire set of probes (Fig. 6A), or the DEGs revealed in each comparison (Fig. 6B and 6C): all
309 these elaborations revealed a clear separation between CTRL and exposed mussels along the x axis,
310 while the clustering of NIM and KET groups would suggest similarities of gene expression profiles
311 in response to such pharmaceuticals.

312 Functional interpretation of differentially transcribed genes was obtained through
313 enrichment analysis with DAVID software (Table 4). Among the most interesting enriched
314 Biological Processes (BP) and KEGG pathways, KET revealed “proteolysis” (represented by 25
315 DEGs), “monosaccharide metabolic process” (8 DEGs), “NOD-like receptor signaling pathway” (7

316 DEGs), “Apoptosis” (7 DEGs) and “p53 signaling pathway” (6 DEGs); enrichment analysis of
317 DEGs in response to NIM revealed a total of 14 BP and 5 KEGG pathways including “response to
318 stimulus” (43 DEGs), “oxidation reduction” (45 DEGs), “response to stress” (26 DEGs), “response
319 to xenobiotic stimulus” (4 DEGs), “immune response” (6 DEGs), “Metabolism of xenobiotics by
320 cytochrome P450” (5 DEGs), and “Apoptosis” (7 DEGs). Beside the above-mentioned BP and
321 KEGG pathways, mussels exposed to both the NSAIDs showed the modulation of several genes
322 involved in the arachidonic acid (AA) metabolism, carbohydrate and fatty acid metabolism,
323 immune responses, DNA repair, apoptosis, cell cycle: full lists of enriched BP and KEGG
324 pathways, and of significant genes involved in each process/pathways are reported in
325 Supplementary Material 4 and 5 (SM4, SM5), respectively.

326 4. Discussion

327 Pharmaceuticals represent one of the most relevant groups of emerging contaminants in
328 aquatic ecosystems (Zenker et al., 2014), and understanding their biological consequences on
329 aquatic wildlife has become a research priority. Despite the marine environment has been
330 considered as not affected by these pollutants for dilution, dispersion and degradation processes
331 (Fabbri, 2015), recent studies demonstrated the presence of widely used non-steroidal anti-
332 inflammatory pharmaceuticals in tissues of wild mussels populations from the Adriatic coast
333 (Mezzelani et al., 2016). The onset of adverse effects in marine organisms exposed to different
334 classes of neuroactive, anti-inflammatory and cardiovascular pharmaceuticals (Fabbri, 2015;
335 Gonzalez-Rey and Bebianno, 2014; Mezzelani et al., 2016), further corroborated the need of a
336 better characterization of this environmental risk.

337 The aim of the present study was to compare the sensitivity of biomarker responses
338 previously highlighted in mussels exposed at 25 µg/L of various NSAIDs (Mezzelani et al., 2016),
339 with a much lower, environmentally realistic exposure concentration (0.5 µg/L); higher values of
340 these pharmaceuticals have already been reported for in the Mediterranean Sea (Togola and
341 Budzinski, 2008; Loos et al., 2013; Nodler et al., 2014). The responsiveness of mussels was
342 addressed in terms of bioaccumulation potential of these compounds, and integrating functional
343 biological effects at cellular level with the earlier, transcriptional modulation of genes measured at
344 molecular level. **In our experiments, we considered nominal concentrations as exposure levels since
345 water was changed and molecules re-dosed on a daily basis: however, particularly in field studies,
346 measurements of these compounds in water may certainly contribute to better clarify the
347 bioaccumulation processes in different non-target species.**

348 Our results clearly highlighted the possibility for marine organisms to accumulate
349 pharmaceuticals over a wide range of environmental levels. Tissue concentrations of DIC and NIM

350 increased after 14 days of exposure, suggesting a possible dose dependent behaviour, when
351 compared to values measured in mussels exposed to 50 folds higher levels of the same
352 pharmaceuticals (Mezzelani et al., 2016). On the other hand, IBU, previously accumulated after
353 exposure to 25µg/L, remained below the detection limit in this study; both AMP and KET
354 confirmed a lack of bioaccumulation in mussels tissues, independently on the exposure doses used
355 either in the present or in the previous investigation (Mezzelani et al., 2016). However, an
356 ecotoxicological concern was evidenced for all tested compounds even with limited or absent
357 bioaccumulation, supporting the hypothesis that original compounds can be, at least partly,
358 transformed by environmental or biological processes (Kümmerer, 2009; Bebianno and Gonzalez-
359 Rey, 2015). The biological reactivity of NSAIDs without a specific marker of exposure may
360 represent an important challenge for characterizing the environmental consequences of
361 pharmaceuticals in field conditions.

362 Several biomarkers which appeared modulated after exposure to 25 µg/L (Mezzelani et al.,
363 2016), were affected also in this study, although the magnitude of observed variations was lower
364 and often not statistically significant. Destabilization of lysosomal membranes and enhanced
365 accumulation of lipofuscin in tertiary lysosomes were caused by all NSAIDs at elevated
366 concentrations (Mezzelani et al., 2016), while significant effects appeared in this study in mussels
367 exposed to 0.5 µg/L of IBU, DIC or NIM. Similarly, the reduction of neutral lipids content and
368 inhibition of ACOX observed at high doses of pharmaceuticals, were less marked at
369 environmentally realistic levels. Overall, these results confirm the lysosomal compartment, lipid
370 peroxidation and lipid metabolism as key cellular targets of tested drugs with an early onset of
371 responsiveness at low exposure levels and increased effects at higher doses. The impairment of
372 lysosomal membranes confirm a mode of action elicited by NSAIDs in aquatic invertebrates
373 (Aguirre Martínez et al., 2013; Gonzalez-Rey and Bebianno, 2014; Parolini et al., 2011) while
374 information on the potential role of those compounds in modulating lipid metabolisms, β-oxidation
375 of the fatty acids and consumption of energy reserves, is still limited and partly supported by similar
376 effects in rat liver and isolated mitochondria (Zhao et al., 1992). Organisms exposed to low levels
377 of KET exhibited a significant increase of granulocytes-hyalinocytes ratio and of phagocytosis
378 activity, which might reflect changes in cell cycle induced by NSAIDs, as previously demonstrated
379 for mammals (Chang et al., 2009): despite the functionality of different haemocytes subpopulations
380 is still debated for invertebrates, granulocytes seem mainly involved in phagocytosis, while
381 hyalinocytes would be specialized in coagulation and encapsulation processes (Carballal et al.,
382 1997; García- García et al., 2008; Giulianini et al., 2003; Gorbi et al., 2012, 2013).

383 Acetylcholinesterase activity was inhibited in haemolymph of mussels exposed to NIM
384 while more limited effects were caused by other NSAIDs and in gills. The comparison of obtained
385 results with those of previous investigations, suggests variable trends and biphasic variations of
386 AChE in response to NSAIDs; a slight enzymatic enhancement in haemolymph was caused by 25
387 µg/L of AMP, DIC, KET and NIM, and by 250 ng/L of DIC in gills, while in the latter tissue AChE
388 was inhibited by AMP (Gonzalez-Rey and Bebianno, 2014; Mezzelani et al., 2016). Considering
389 the key role of acetylcholinesterase in terminating neurotransmission at cholinergic synapses and its
390 modulation by a broad spectrum of xenobiotics, further studies are necessary to support the
391 hypothesis that NSAIDs influence this enzyme through species- and tissue-specific mechanisms of
392 action.

393 Responses of antioxidant defences toward low doses of NSAIDs were almost negligible
394 compared to the slight but significant changes of catalase, glutathione S-transferases and TOSC
395 toward hydroxyl radicals observed after exposure to 25 µg/L (Mezzelani et al., 2016). The lack of
396 oxidative challenge observed in this study would confirm that prooxidant mechanisms do not
397 represent the primary mode of action of these pharmaceuticals as already reported for marine
398 mussels exposed to DIC and IBU (Gonzalez-Rey and Bebianno, 2014). Consistently with the onset
399 of slight signals of cellular perturbations at environmental exposure doses, DNA fragmentation and
400 frequency of micronuclei tended to increase in mussels exposed to KET, NIM and, to a lower
401 extent, DIC. Although these effects were of limited magnitude, they still represent early warning
402 signals for the same typology of alterations more clearly detected at higher doses of NSAIDs
403 (Mezzelani et al., 2016; Parolini et al., 2011).

404 The multivariate PCA analysis of biomarkers provided a clear separation between control
405 mussels and those exposed to various NSAIDs especially DIC, NIM and KET, confirming for the
406 latter that the onset of biological effects is not necessarily related to a measurable accumulation of
407 the compound. The biological relevance of observed effects was further highlighted by the
408 elaboration of the overall results in a cellular hazard index. Although biomarkers can be useful in
409 revealing early effects and mechanisms of action of environmental pollutants, their full potential is
410 greatly enhanced when complex data obtained from multiple cellular pathways can be summarized
411 in a cellular hazard or health index. In this respect, scientific literature provides several examples of
412 integrative procedures based on the toxicological knowledge of biomarkers, which represent a
413 valuable approach to present scientifically sound data in a user-friendly format, easy for non-expert
414 stakeholders or decision-makers (Beliaeff and Burgeot, 2002; Piva et al., 2011; Broeg et al., 2005;
415 Dagnino et al., 2008; Benedetti et al., 2012). Despite different algorithms and assumptions, such
416 integrative procedures were shown to represent and added value, being all comparable in

417 discriminating altered health conditions (Marigómez et al., 2013). The calculations applied in the
418 present investigation are part of a more complex Weight of Evidence model (Sediqualsoft) which
419 uses weighted criteria to elaborate and integrate different typologies of data, as previously validated
420 in several risk assessment studies (Benedetti et al., 2012, 2014; Regoli et al., 2014; Avio et al.,
421 2015; Bebianno et al., 2015). When the biological significance of observed variations was
422 quantified weighting the number, toxicological relevance and magnitude of effects, the cellular
423 hazard was classified as “Slight” for AMP, DIC, IBU and NIM exposed organisms, “Moderate” for
424 KET. The hazard index obtained after the exposure to 25µg/L was “Moderate” for all NSAIDs,
425 further demonstrating that lower levels of pharmaceuticals affected the same cellular pathways at a
426 quantitatively lower extent. Such elaboration of complex biological data in an hazard index allow
427 easy comparisons between molecules, doses and exposure conditions, eliciting quantitatively
428 different effects in non-target organisms and giving useful insights for a prioritization of
429 pharmaceuticals within an Environmental Risk Assessment framework.

430 Considering the lack of accumulation for KET but the onset of cellular alterations in mussels
431 exposed to this compound, it was of interest to further test the hypothesis of the possible lack of
432 correlation between tissue concentrations of pharmaceuticals and biological effects at molecular
433 level. Analyses on transcriptional profiles provided additional insights on activation of molecular
434 mechanisms, suggesting a similar MOA by the comparison of gene expression profiles in mussels
435 exposed to KET and NIM. In analogy with cellular biomarkers, pathways involved in
436 immunological functions and fatty acid metabolism appeared among the primary responses to both
437 the NSAIDs: a coordinated activation of innate immune defences was clearly indicated by the
438 significant changes in a large number of genes which regulate lysosomal enzymes, toll-like
439 receptors (TLRs), lectins and scavenger receptors (see SM 5).

440 Noteworthy, substantial effects were also observed in the regulation of genes involved in
441 arachidonic acid (AA) metabolism. In mammals, NSAIDs act as inhibitors of cyclooxygenase
442 (COX), which is responsible for the formation of eicosanoids (prostaglandins, thromboxanes,
443 leukotrienes) from AA. In the present study, the common up-regulation of PLA2 and down-
444 regulation of TBXAS1, PGR1, PTGER4, and CYP4 (Table 4 and SM 5) suggest a COX-based
445 mode of action for both KET and NIM, with an inhibition of eicosanoids synthesis in exposed
446 mussels. A similar mechanism has already been suggested in other invertebrate species (Heckman
447 et al., 2008; Milan et al. 2013a; Rowley et al., 2005) which corroborates the potential
448 ecotoxicological effects of NSAIDs in marine organisms, considering the role of eicosanoids in
449 reproduction (Stanley et al. 2000), gametogenesis (Heckman et al., 2008; Rowley et al., 2005) and
450 larval settlement (Knight et al., 2000).

451 Molecular analyses revealed the down-regulation of *acyl-Coenzyme A oxidase 1* (ACOX1)
452 and *acetyl-CoA acyltransferase 2* (ACAA2) in KET and NIM exposed mussels, respectively. These
453 results confirm the earlier responsiveness of transcriptional modulation compared to cellular
454 biomarkers at low exposure levels: reduced ACOX activities appeared as a trend in this study, but
455 such, statistically significant functional effects were clearly observed in mussels at higher exposure
456 doses (Mezzelani et al., 2016). The relationship between NSAIDs and lipid metabolism may be
457 directly explained by the high affinity of these pharmaceuticals for peroxisome proliferator-
458 activated receptors (PPARs) (Auwerx, 1999; Lehman et al., 1997).

459 The slight enhancement of DNA damage observed at cellular level in mussels exposed to
460 KET and NIM, can be linked to the molecular up-regulation of RAD1 and SESN1. RAD1 is a
461 component of cell cycle checkpoint complex that permits DNA repair preventing cell cycle
462 progression (Volkmer and Karnitz, 1999). SESN1 is a stress-inducible gene with a role in the
463 cellular response to DNA damage and oxidative stress, previously found to be up-regulated also in
464 Manila clam exposed to ibuprofen (Milan et al., 2013a). Additional genes involved in control of the
465 cell cycle and differentiation, such as *cyclin-dependent kinase 6* (CDK6), *cell division cycle 26*
466 *homolog* (CDC26), and *menage a trois homolog 1* (MNAT1), were significantly up-regulated in
467 both KET and NIM exposed mussels, confirming the hypothesis of potential effects of NSAIDs on
468 those pathways (Mezzelani et al., 2016).

469 Apoptosis was also found as an enriched KEGG in NIM and KET exposed mussels (SM4)
470 with up-regulation of several genes, such as putative *baculoviral IAP repeat-containing 2* (BIRC2)
471 and *X-linked inhibitor of apoptosis* (XIAP), *BCL2-associated athanogene 4* (BAG4), *B-cell*
472 *CLL/lymphoma 2* (BCL2), and *BCL2-Like 1* (BCL2L1), and down-regulation of *caspase 2*
473 (CASP2), *caspase 3* (CASP3) and *caspase 7* (CASP7). BIRC2 and XIAP are members of the
474 apoptosis inhibitors family by interfering with the activation of caspase 3, 7 and 9, BCL2 encodes
475 an integral outer mitochondrial membrane protein that blocks the apoptotic death, while BAG4
476 belongs to the anti-apoptotic protein BAG1 family that may markedly increase the anti-cell death
477 function of BCL2 (Takayama et al., 1995). Over-expression of BIRC2, XIAP, BCL2 and BAG4
478 was previously observed in clams exposed to ibuprofen (Milan et al 2013a), suggesting increased
479 anti-apoptotic activity as a common response to NSAIDs in bivalves. Despite the still limited
480 knowledge on molecular regulation of apoptosis in marine species, the observed transcriptional
481 changes suggest similarities with the signaling pathways identified in other model organisms.

482 In conclusion, this study confirmed that some NSAIDs could be accumulated in mussels
483 tissues also at very low, environmentally realistic levels. However, our results also demonstrated for
484 the first time that ecotoxicological potential of pharmaceuticals is not necessarily reflected by tissue

485 concentrations of these compounds, suggesting the possibility of biotransformation and/or excretion
486 mechanisms. Such a lack of correlation between accumulation and molecular-cellular effects is a
487 well-known possibility in aquatic toxicology, like for polycyclic aromatic hydrocarbons in fish.
488 The onset of biological effects was evident at molecular level, with clear modulation of a large
489 number of genes involved in the arachidonic acid metabolism, immune responses, apoptosis, cell
490 cycle and DNA repair. Molecular analyses supported the typology of functional variations observed
491 among cellular biomarkers with immune system responses, lipid metabolism and genotoxic effects,
492 as the main targets of NSAIDs in marine organisms. Similar data may represent the basis for the
493 future development of an Adverse Outcome Pathway, designing appropriate experiments to provide
494 clear-cut mechanistic representation of critical toxicological effects spanning over different levels
495 of biological organization.

496 In the present work, alterations observed at various levels of biological organization
497 exhibited a different quantitative modulation by dose of exposure. Transcriptional responses were
498 more sensitive and activated even at low environmental levels of NSAIDs, when catalytic and
499 cellular alterations were still of limited magnitude, becoming evident at higher exposure doses. In
500 this respect, links between transcriptional and functional effects are not necessarily present,
501 confirming the complexity of such relationships, which are modulated by several factors, including
502 intensity and time of exposure.

503 Our data are obviously not conclusive, but the obtained results are promising and of
504 potential interest to scientists, governments and industry. On one hand, they demonstrated
505 biological responsiveness of pharmaceuticals in marine organisms, corroborating the utility of
506 further studies, including exposures to multiple doses, mixtures and long-term periods, to clarify
507 mode of action of NSAIDs in non-target species, and to explore possible links between cellular
508 effects, physiological and ecological consequences. On the other hand, the present study also
509 highlights the urgency to include pharmaceutical contaminants in normative guidelines and
510 monitoring protocols for the assessment of good ecological status of marine environment, and the
511 recommendation to consider ecotoxicological effects when designing new active molecules or
512 prescribing already existing commercial compounds.

513 **5. Data accessibility**

514 The following link has been created to allow review of record GSE66990 while it remains in private
515 status:

516 <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=qnshskicbbehdmb&acc=GSE66990>

519 **6. Acknowledgements**

1
520 We are grateful to the EU Project REPROSEED (245119) that provided transcriptomic information
3
521 on *Mytilus galloprovincialis* employed for DNA microarray design.
5

6
522

8
9
523 **7. References**

10
11
124 Aguirre-Martínez, G.V., Buratti, S., Fabbri, E., Del Valls, A.T., Martín-Díaz, M.L., 2013.
13
525 Using lysosomal membrane stability of haemocytes in *Ruditapes philippinarum* as a biomarker of
15
526 cellular stress to assess contamination by caffeine, ibuprofen, carbamazepine and novobiocin. J.
17
527 Environ. Sci. 25, 1408-1418.
18

19
528 Al Aukidy, M., Verlicchi, P., Jelic, A., Petrovic, M., Barcelò, D., 2012. Monitoring release
20
529 of pharmaceutical compounds: occurrence and environmental risk assessment of two WWTP
22
530 effluents and their receiving bodies in the Po Valley, Italy. Sci. Total Environ. 438, 15-25.
24

25
531 Andreozzi, R., Marotta, R., Nicklas, P., 2003. Pharmaceuticals in STP effluents and their
26
532 solar photodegradation in aquatic environment. Chemosphere 50, 1319-1330.
27

28
533 Ankley, G.T., Brooks, B.W., Huggett, D.B., Sumpter, J.P., 2007. Repeating history:
29
534 Pharmaceuticals in the environment. Environ. Sci. Technol. 41, 8211-8217.
30
31

32
535 Ashton, D., Hilton, M., Thomas, K.V., 2004. Investigating the environmental transport of
33
536 human pharmaceuticals to streams in the United Kingdom. Sci. Total Environ. 333, 167-184.
35

36
537 Auwerx, J., 1999. PPAR gamma, the ultimate thrifty gene. Diabetologia. 42(9), 1033-1049.
37

38
538 Avio, C.G., Gorbi, S., Milan, M., Benedetti, M., Fattorini, D., d'Errico, G., Pauletto, M.,
39
539 Bargelloni, L., Regoli, F., 2015. Pollutants bioavailability and toxicological risk from microplastics
40
540 to marine mussels. Environ. Pollut. 198, 211-222.
41
42

43
541 Bayen, S., Zhang, H., Desai, M.M., Ooi, S.K., Kelly, B.C., 2013. Occurrence and
44
542 distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine
46
543 environment: influence of hydrodynamics and physical–chemical properties. Environ. Pollut. 182,
48
544 1-8.
49

50
545 Bebianno, M.J., Gonzalez-Rey M., 2015. Ecotoxicological Risk of Personal Care Products
51
546 and Pharmaceuticals in Claude Amiard-Triquet, Jean-Claude Amiard and Catherine Mouneyrac,
53
547 Aquatic Ecotoxicology, Advancing Tools for Dealing with Emerging Risks. Academic Press Ch.
55
548 16, 383-416.

57
549 **Beliaeff, B., Burgeot, T., 2002. Integrated biomarker response: a useful tool for ecological**
58
59 **risk assessment. Environ. Toxicol. Chem. 21, 1316-1322.**
60

551 Bendz, D., Paxéus, N.A., Ginn, T.R., Loge, F.J., 2005. Occurrence and fate of
552 pharmaceutically active compounds in the environment, a case study: Höje River in Sweden. J.
553 Hazard. Mater. 122, 195-204.

554 Benedetti, M., Ciaprini, F., Piva, F., Onorati, F., Fattorini, D., Notti, A., Ausili, A., Regoli,
555 F., 2012. A multidisciplinary weight of evidence approach toward polluted sediments: integrating
556 sediment chemistry, bioavailability, biomarkers responses and bioassays. Environ. Int. 38, 17-28.

557 Benedetti, M., Gorbi, S., Fattorini, D., D'Errico, G., Piva, F., Pacitti, D., Regoli F., 2014.
558 Environmental hazards from natural hydrocarbons seepage: integrated classification risk from
559 sediment chemistry, bioavailability and biomarker responses in sentinel species Environ. Pollut.
560 185, 116-126.

561 Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., *et al.* 2012. Pharmaceuticals and
562 personal care products in the environment: what are the big questions? Environ. Health Perspect.
563 120, 1221-1229.

564 Broeg, K., Westernhagen, H.V., Zander, S., Körting, W., Koehler, A., 2005. The “bioeffect
565 assessment index” – a concept for the quantification of effects of marine pollution by an integrated
566 biomarker approach. Mar. Pollut. Bull. 50, 495-503.

567 Buser, H.R., Poiger, T., Müller, M.D., 1999. Occurrence and environmental behavior of the
568 pharmaceutical drug ibuprofen in surface waters and in wastewater. Environ. Sci. Technol. 33,
569 2529-2535.

570 Carballal, M.J., Lopez, M.C., Azevedo, C., Villalba, A., 1997. Hemolymph cell types of the
571 mussel *Mytilus galloprovincialis*. Dis. Aquat. Org. 29, 127-135.

572 Carmona, E., Andreu, V., Picó, Y., 2014. Occurrence of acidic pharmaceuticals and personal
573 care products in Turia River Basin: from waste to drinking water. Sci. Total Environ. 484, 53-63.

574 Castiglioni, S., Bagnati, R., Calamari, D., Fanelli, R., Zuccato, E., 2005. A multi residue
575 analytical method using solid-phase extraction and high-pressure chromatography tandem mass
576 spectrometry to measure pharmaceuticals of different therapeutic classes in urban wastewaters. J.
577 Chromatogr. A 1092, 206-215.

578 Chang, J.K., Li, C.J., Liao, H.J., Wang, C.K., Wang, G.J., Ho, M.L., 2009. Anti-
579 inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell
580 cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology. 258, (2-3)
581 148-156.

582 Dagnino, A., Sforzini, S., Dondero, F., Fenoglio, S., Bona, E., Jensen, J., Viarengo, A.,
583 2008. A “Weight-of-Evidence” approach for the integration of environmental “Triad” data to
584 assess ecological risk and biological vulnerability. Integr. Environ. Assess. Manage. 4, 314-326.

585 Fabbri, E., 2015. Pharmaceuticals in the environment: expected and unexpected effects on
1 aquatic fauna. Ann. N. Y. Acad. Sci. 1340, 20-28.
2
3
587 Fabbri, E., Franzellitti, S., 2015. Human pharmaceuticals in the marine environment: focus
4
588 on exposure and biological effects in animal species. Environ. Toxicol. Chem. 35 (4), 799-812.
6
589 Fang, T.H., Nan, F.H, Chin, T.S, Feng, H.M. 2012. The occurrence and distribution of
8 pharmaceutical compounds in the effluents of a major sewage treatment plant in Northern Taiwan
990 and the receiving coastal waters. Mar. Pollut. Bull. 64, 1435-1444.
10
1591 Fent, K., Weston, A.A., Caminada, D., 2006. Ecotoxicology of human pharmaceuticals.
12
1592 Aquat. Toxicol. 76, 122-159.
14
1593 Ferrari, F., Gallipoli, A., Balderacchi, M., Ulaszewska, M.M., Capri, E., Trevisan, M., 2011.
16
1594 Exposure of the Main Italian River Basin to Pharmaceuticals. J. Toxicol 2011, 989270.
17
1595 Gagné, F., Berube, E., Fournier, M., Blaise, C., 2005. Inflammatory properties of municipal
19 effluents to *Elliptio complanata* mussels: lack of effects from anti-inflammatory drugs. Comp.
21
2597 Biochem. Physiol. C Toxicol. Pharmacol. 141, 332-337.
23
2598 García-García, E., Prado-Álvarez, M., Novoa, B., Figueras, A., Rosales, C., 2008. Immune
25 responses of mussel hemocyte subpopulations are differentially regulated by enzymes of the PI 3-K,
27
2600 PKC, and ERK kinase families. Dev. Comp. Immunol. 32, 637-653.
28
2601 Giuliani, M.E., Benedetti, M., Arukwe, A., Regoli, F., 2013. Transcriptional and catalytic
30
2602 responses of antioxidant and biotransformation pathways in mussels, *Mytilus galloprovincialis*,
32
2603 exposed to chemical mixtures. Aquat. Toxicol. 134–135, 120–127.
34
2604 Giulianini, P.G., Bertolo, F., Battistella, S., Amirante, G.A., 2003. Ultrastructure of the
36
2605 hemocytes of *Cetonischema aeruginosa* larvae (Coleoptera, Scarabaeidae): involvement of both
38
2606 granulocytes and oenocytoids in vivo phagocytosis. Tissue Cell 35, 243-251.
39
2607 Gómez, M.J., Martínez Bueno, M.J., Lacorte, S., Fernández-Alba, A.R., Agüera A., 2007. Pilot
41 survey monitoring pharmaceuticals and related compounds in a sewage treatment plant located on
43
2609 the Mediterranean coast. Chemosphere 66, 993-1002.
45
2610 Gonzalez-Rey, M., Bebianno, M.J., 2014. Effects of non-steroidal anti-inflammatory drug
47
2611 (NSAID) diclofenac exposure in mussel *Mytilus galloprovincialis*. Aquat. Toxicol. 148, 221-230.
48
2612 Gonzalez-Rey, M., Tapie, N., Le Menach, K., Dévier, M.H., Budzinski, H., Bebianno, M.J.,
50
2613 2015. Occurrence of APIS and pesticides in aquatic systems. Mar. Pollut. Bull. 96, 384-400.
52
2614 Gorbi, S., Bocchetti, R., Binelli, A., Bacchiocchi, S., Orletti, R., Nanetti, L., Raffaelli, F.,
54
2615 Vignini, A., Accoroni, S., Totti, C., Regoli, F., 2012. Biological effects of palytoxinlike compounds
56
2616 from *Ostreopsis cf. ovata*: a multibiomarkers approach with mussels *Mytilus galloprovincialis*.
58
2617 Chemosphere 89, 623-632.
59
2618

619 Gorbi, S., Avio, C.G., Benedetti, M., Totti, C., Accoroni, S., Pichierri, S., Bacchiocchi, S.,
620 Orletti, R., Graziosi, T., Regoli, F., 2013. Effects of harmful dinoflagellate *Ostreopsis cf. ovata*
621 exposure on immunological, histological and oxidative responses of mussels *Mytilus*
622 *galloprovincialis*. Fish Shellfish Immunol. 35, 941-950.

623 Gros, M., Petrovic, M., Barceló, D., 2006. Development of a multi-residue analytical
624 methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for
625 screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta 70,
626 678-690.

627 Gros, M., Rodríguez-Mozaz, S., Barceló, D., 2012. Fast and comprehensive multi-residue
628 analysis of a broad range of human and veterinary pharmaceuticals and some of their metabolites in
629 surface and treated waters by ultra-high-performance liquid chromatography coupled to quadrupole-
630 linear ion trap tandem mass spectrometry. J. Chromatogr. A 1248, 104-121.

631 Heckmann, L.H., Sibly, R.M., Connon, R., Hooper, H.L., Hutchinson, T.H., Maund, S.J., Hill,
632 C.J., Bouetard, A., Callaghan, A., 2008. Systems biology meets stress ecology: linking molecular
633 and organismal stress responses in *Daphnia magna*. Genome Biol. 9, R40.

634 Heberer, T., Dünbier, U., Reilich, C., Stan, H.J., 1997. Detection of drugs and drug metabolites
635 in ground water samples of a drinking water treatment plant. Fresen. Environ. Bull. 6, 438-443.

636 Heberer, T., Reddersen, K., 2001. Occurrence and fate of pharmaceutical residues in the aquatic
637 system of Berlin as an example for urban ecosystems. Proceedings of the Second International
638 Conference on Pharmaceuticals and Endocrine Disrupting Chemicals in Water. Minneapolis, USA.

639 Huang, D.W., Sherman, B.T., Lempicki, R.A., 2009. Systematic and integrative analysis of
640 large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.

641 Johnson, W.E., Li, C., Rabinovic, A., 2007. Adjusting batch effects in microarray expression
642 data using empirical Bayes methods. Biostatistics 8, 118-127.

643 Kim, Y., Choi, K., Jung, J., Park, S., Kim, P.G., Park, J., 2007. Aquatic toxicity of
644 acetaminophen, carbamazepine, cimetidine, diltiazem and six major sulfonamides, and their
645 potential ecological risks in Korea. Environ. Int. 33, 370-375.

646 Knight, J., Rowley, A.F., Yamazaki, M., Clare, A.S., 2000. Eicosanoids are modulators of larval
647 settlement in the barnacle, *Balanus amphitrite*. J. Mar. Biol. Assn UK 80, 113-117.

648 Kümmerer, K., 2009. The presence of pharmaceuticals in the environment due to human use -
649 present knowledge and future challenges. J. Environ. Manag. 90, 2354-2366.

650 Lacey, C., Basha, S., Morrissey, A., Tobin, J.M., 2012. Occurrence of pharmaceutical
651 compounds in wastewater process streams in Dublin, Ireland. Environ. Monit. Asses. 184, 1049-
652 1062.

653 Lee, H.B., Peart, T.E., Svoboda M.L., 2005. Determination of endocrine-disrupting phenols,
654 acidic pharmaceuticals, and personal-care products in sewage by solid-phase extraction and gas
655 chromatography-mass spectrometry. *J. Chromatogr. A* 1094, 122-129.

656 Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., Kliewer, S.A., 1997. Peroxisome
657 proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-
658 inflammatory drugs. *J. Biol. Chem.* 272, 3406-3410.

659 Lin, A.Y.C., Tsai, Y.T., 2009. Occurrence of pharmaceuticals in Taiwan's surface waters:
660 Impact of waste streams from hospitals and pharmaceutical production facilities. *Sci. Total*
661 *Environ.* 407, 3793-3802.

662 Lolić, A., Paíga, P., Santos, L.H.M.L.M., Ramos, S., Correia, M., Delerue-Matos, C., 2015.
663 Assessment of non-steroidal anti-inflammatory and analgesic pharmaceuticals in seawaters of North
664 of Portugal: occurrence and environmental risk. *Sci. Total Environ.* 508, 240-250.

665 Loos, R., Carvalho, R., Antonio, D.C., Cornero, S., Locoro, G., Tavazzi, S., Paracchini, B.,
666 Ghiani, M., Lettieri, T., Blaha, L., Jarosova, B., Voorspoels, S., Servaes, K., Haglund, P., Fick, J.,
667 Lindberg, R.H., Schwesig, D., Gawlik, B.M., 2013. EU wide monitoring survey on emerging polar
668 organic contaminants in wastewater treatment plant effluents. *Water Res.* 47, 6475-6487.

669 Loos, R., Tavazzi, S., Paracchini, B., Canuti, E., Weissteiner, C., 2013. Analysis of polar
670 organic contaminants in surface water of the northern Adriatic Sea by solid-phase extraction
671 followed by ultrahigh-pressure liquid chromatography-QTRAP(A (R)) MS using a hybrid triple-
672 quadrupole linear ion trap instrument. *Anal. Bioanal. Chem.* 405, 5875-5885.

673 Marigómez, I., Zorita, I., Izagirre, U., Ortiz-Zarragoitia, M., Navarro, P., Etxebarria, N., Orbea,
674 A., Soto, M., Cajaraville, M.P., 2013. Combined use of native and caged mussels to assess
675 biological effects of pollution through the integrative biomarker approach. *Aquat. Toxicol.* 136-137,
676 32-48.

677 McEneff, G., Barron, L., Kelleher, B., Paull, B., Quinn, B., 2014. A year-long study of the
678 spatial occurrence and relative distribution of pharmaceutical residues in sewage effluent, receiving
679 marine waters and marine bivalves. *Sci. Total. Environ.* 476-477, 317-326.

680 Metcalfe, C.D., Koenig, B.G., Bennie, D.T., Servos, M., Ternes, T.A., Hirsch, R., 2003.
681 Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants.
682 *Environ. Toxicol. Chem.* 22, 2872-2880.

683 Mezzelani, M., Gorbi, S., Da Ros, Z., Fattorini, D., d'Errico, G., Milan, M., Bargelloni, L.,
684 Regoli F., 2016. Ecotoxicological potential of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
685 in marine organisms: bioavailability, biomarkers and natural occurrence in *Mytilus*
686 *galloprovincialis*. *Mar. Environ. Res.* In press. [http:// dx.doi.org/10.1016/j.marenvres.2016.03.005](http://dx.doi.org/10.1016/j.marenvres.2016.03.005)

687 Milan, M., Coppe, A., Reinhardt, R., Cancela, L.M., Leite, R.B., Saavedra, C., Ciofi, C.,
688 Chelazzi, G., Patarnello, T., Bortoluzzi, S., Bargelloni, L., 2011. Transcriptome sequencing and
689 microarray development for the Manila clam, *Ruditapes philippinarum*: genomic tools for
690 environmental monitoring. BMC Gen. 12, 234.

691 Milan, M., Pauletto, M., Patarnello, T., Bargelloni, L., Marin, M.G., Matozzo, V., 2013a. Gene
692 transcription and biomarker responses in the clam *Ruditapes philippinarum* after exposure to
693 ibuprofen. Aquat. Toxicol. 126, 17-29.

694 Milan, M., Ferraresso, S., Ciofi, C., Chelazzi, G., Carrer, C., Ferrari, G., Pavan, L., Patarnello,
695 T., Bargelloni, L., 2013b. Exploring the effects of seasonality and chemical pollution on the
696 hepatopancreas transcriptome of the Manila clam. Mol. Ecol. 22 (8), 2157-2172.

697 Nakada, N., Tanishima, T., Shinohara, H., Kiri, K., Takada, H., 2006. Pharmaceutical
698 chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during
699 activated sludge treatment. Water Res. 40, 3297-3303.

700 Nebot, C., Gibb, S.W., Boyd, K.G., 2007. Quantification of human pharmaceuticals in water
701 samples by high performance liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta.
702 598, 87-94.

703 Nödler, K., Voutsas, D., Licha, T., 2014. Polar organic micropollutants in the coastal
704 environment of different marine systems. Mar. Pollut. Bull. 85, 50-59.

705 Paíga, P., Santos, H.M.L.M., Amorim, C.G., Araújo, A.N., Montenegro, M.C., Pena, A.,
706 Delerue-Matos, C., 2013. Pilot monitoring study of ibuprofen in surface waters of north of Portugal.
707 Environ. Sci. Pollut. Res. 20, 2410-2420.

708 Pailler, J.Y., Krein, A., Pfister, L., Hoffmann, L., Guignard, C., 2009. Solid phase extraction
709 coupled to liquid chromatography-tandem mass spectrometry analysis of sulfonamides,
710 tetracyclines, analgesics and hormones in surface water and wastewater in Luxembourg. Sci. Total
711 Environ. 407, 4736-4743.

712 Pal, A., Gin, A.Y.C., Reinhard, M., 2010. Impacts of emerging organic contaminants on
713 freshwater resources: review of recent occurrences, sources, fate and effects. Sci. Total Environ. 8,
714 6062-6069.

715 Parolini, M., Binelli, A., Provini, A., 2011. Chronic effects induced by ibuprofen on the
716 freshwater bivalve *Dreissena polymorpha*. Ecotoxicol. Environ. Saf. 74, 1586-1594.

717 Petrie, B., Barden, R., Kasprzyk-Hordern, B., 2014. A review on emerging contaminants in
718 wastewaters and the environment: current knowledge, understudied areas and recommendations for
719 future monitoring. Water Res. 30, 1-25.

720 Piva, F., Ciaprini, F., Onorati, F., Benedetti, M., Fattorini, D., Ausili, A., Regoli, F., 2011.
721 Assessing sediment hazard through a Weight Of Evidence approach with bioindicator organisms: a
722 practical model to elaborate data from sediment chemistry, bioavailability, biomarkers and
723 ecotoxicological bioassays. *Chemosphere* 83, 475-485.

724 Regoli, F., Giuliani, M.E., 2014. Oxidative pathways of chemical toxicity and oxidative stress
725 biomarkers in marine organisms. *Mar. Environ. Res* 93, 106-117.

726 Regoli, F., Giuliani, M.E., Benedetti, M., Arukwe, A., 2011. Molecular and biochemical
727 biomarkers in environmental monitoring: A comparison of biotransformation and antioxidant
728 defence systems in multiple tissues. *Aquat. Toxicol.* 105S (2011), 56– 66.

729 Regoli, F., Pellegrini, D., Cicero, A.M., Nigro, M., Benedetti, M., Gorbi, S., Fattorini, D.,
730 D'Errico, G., Di Carlo, M., Nardi, A., Gaion, A., Scuderi, A., Giuliani, S., Romanelli, G., Berto, D.,
731 Trabucco, B., Bernardeschi, M., Guidi, P., Scarcella, V., Frenzilli G., 2014. A multidisciplinary
732 weight of evidence approach for environmental risk assessment at the Costa Concordia wreck:
733 integrative indices from Mussel Watch. *Mar. Environ. Res.* 96, 92-104.

734 Roberts, P.H., Bersuder, P., 2006. Analysis of OSPAR priority pharmaceuticals using high -
735 performance liquid chromatography-electrospray ionization tandem mass spectrometry. *J.*
736 *Chromatogr. A* 1134, 143–150.

737 Rodriguez-Navas, C., Bjoerklund, E., Bak, S.A., Hansen, M., Krogh, K.A., Maya, F., Forteza,
738 R., Cerda, V., 2013. Pollution pathways of pharmaceutical residues in the aquatic environment on
739 the Island of Mallorca, Spain. *Arch. Environ. Contam. Toxicol.* 65,56-66.

740 Rowley, A.E., Vogan, C.L., Taylor, G.W., Clare, A.S., 2005. Prostaglandins in non-insectan
741 invertebrates: recent insights and unsolved problems. *J. Exp. Biol.* 208 (Pt 1), 3-14.

742 Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M.,
743 Currier, T., Thiagarajan, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A.,
744 Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., Quackenbush, J., 2003. TM4: a
745 free, open-source system for microarray data management and analysis. *Biotechniques* 34, 374-378.

746 Salgado, R., Noronha, J. P., Oehmen, A., Carvalho, G., Reis, M. A. M., 2010. Analysis of 65
747 pharmaceuticals and personal care products in 5 wastewater treatment plants in Portugal using a
748 simplified analytical methodology. *Water Sci. Technol.* 62(12), 2862-2871.

749 Santos, J.L., Aparicio, I., Alonso, E., Callejón, M., 2005. Simultaneous determination of
750 pharmaceutically active compounds in wastewater samples by solid phase extraction and high-
751 performance liquid chromatography with diode array and fluorescence detectors. *Anal. Chim. Acta.*
752 550, 116-122.

753 Santos, L.H.M.L.M., Araújo, A.N., Fachini, A., Pena, A., Delerue-Matos, C., Montenegro,
754 M.C.B.S.M., 2010. Ecotoxicological aspects related to the presence of pharmaceuticals in the
755 aquatic environment. *J. Hazard Mater.* 175,45-95.

756 Stanley, D.W., 2000. *Eicosanoids in Invertebrate Signal Transduction Systems*. Princeton
757 University Press, Princeton, NJ.

758 Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Millan, J.A., Reed, J.C. 1995.
759 Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death
760 activity. *Cell* 80(2), 279-284.

761 Tauxe-Wuersch, A., De Alencastro, L.F., Grandjean, D., Tarradellas, J., 2005. Occurrence of
762 several acidic drugs in sewage treatment plants in Switzerland and risk assessment. *Water Res.* 39,
763 1761-1772.

764 Ternes T.A., 1998. Occurrence of drugs in German sewage treatment plants and rivers. *Water*
765 *Res.* **32**, 3245-3260.

766 Thomas, K.V., Hilton, M.J., 2004. The occurrence of selected human pharmaceutical
767 compounds in UK estuaries. *Mar. Pollut. Bull.* 49, 436-444.

768 Thomas, P.M., Foster, G.D., 2004. Determination of non steroidal anti-inflammatory drugs,
769 caffeine, and triclosan in wastewater by gas chromatography-mass spectrometry, *J. Environ. Sci.*
770 *Health. Part A Toxic/Hazard. Subst. Environ. Eng. A* 39, 1969–1978.

771 Togola, A., Budzinski, H., 2008. Multi-residue analysis of pharmaceutical compounds in
772 aqueous samples. *J. Chromatogr. A* 1177, 150-158.

773 Volkmer, E., Karnitz, L.M., 1999. Human homologs of *Schizosaccharomyces pombe* rad1,
774 hus1, and rad9 form a DNA damage-responsive protein complex. *J. Biol. Chem.* 274,567-570.

775 Wang, L., Ying, G.G., Zhao, J.L., Yang, X.B., Chen, F., Tao, R., Liu, S., Zhou, L.J., 2010.
776 Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao
777 River of north China. *Sci. Total Environ.* 408, 3139-3147.

778 Weigel, S., Berger, U., Jensen, E., Kallenborn, R., Thoresen, H., Hühnerfuss, H., 2004.
779 Determination of selected pharmaceuticals and caffeine in sewage and seawater from Tromsø/
780 Norway with emphasis on ibuprofen and its metabolites. *Chemosphere* 56, 583-92.

781 Wu, J., Qian, X., Yang, Z., Zhang, L., 2010. Study on the matrix effect in the determination of
782 selected pharmaceutical residues in seawater by solid-phase extraction and ultra-high performance
783 liquid chromatography-electrospray ionization low-energy collision induced dissociation tandem
784 mass spectrometry. *J. Chromatogr. A* 1217, 1471-1475.

785 Zenker, A., Cicero, M.R., Prestinaci, F., Bottoni, P., Carere, M., 2014. Bioaccumulation and
786 biomagnification potential of pharmaceuticals with a focus to the aquatic environment. *J. Environ.*
787 *Manage.* 133, 378-387.

788 Zhao, B., Geisslinger, G., Hall, I., Day, R.O., Williams, K.M., 1992. The effect of enantiomers
789 of ibuprofen and flurbiprofen on the β -oxidation of palmitate in the rat, *Chirality* 4, 137-141.

790 Zorita, S., Mårtensson, L., Mathiasson, L., 2009. Occurrence and removal of pharmaceuticals in
791 a municipal sewage treatment system in the south of Sweden. *Sci. Total Environ.* 407, 2760-2770.

792 Zuccato, E., Castiglioni, S., Fanelli, R., Reitano, G., Bagnati, R., Chiabrando, C., Pomati, F.,
793 Rossetti, C., Calamari, D., 2006. Pharmaceuticals in the environment in Italy: causes, occurrence,
794 effects and control, *Environ. Sci. Pollut. Res.* 13, 15-21.

795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865

800

TABLES

801 **Table 1.** Environmental concentrations of Acetaminophen, Diclofenac, Ibuprofen, Ketoprofen and
 802 Nimesulide measured in different aquatic bodies.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Compound	Country	Environment	Concentration ng/L	References
Acetaminophen	France	Mediterranean Sea	200000	Togola and Budzinki, 2008
	Greece	Aegean See	2983	Nödler et al., 2014
	Portugal	Arade Estuary	88	Gonzalez Rey et al., 2015
	Spain	Hospital Effluent	500	Kim et al., 2007
	Spain	STP Effluent	32-4200	Kim et al., 2007
	Spain	Mediterranean Sea	23	Gros et al., 2012
	Taiwan	Hospital Effluent	62	Kim et al., 2007
	USA	Groundwater	380	Kim et al., 2007
Diclofenac	Canada	STP Effluent	70-250	Lee et al., 2005
	France	Mediterranean Sea	1500	Togola and Budzinki, 2008
	Germany (Berlin)	STP Effluent	2510	Heberer and Reddensen, 2001
	Germany (Berlin)	STP Effluent	100-131	Fang et al., 2012
	Germany (Berlin)	Groundwater	380	Heberer et al., 1997
	Germany (Frankfurt)	STP Effluent	810-2100	Ternes, 1998
	Greece	STP Effluent	890	Andreozzi et al., 2003
	Ireland	Atlantic Ocean	220-550	McEneff et al., 2014
	Luxembourg	STP Effluent	0.3-78	Paillet et al., 2009
	Portugal	Arade Estuary	31	Gonzalez Rey et al., 2015
	Spain	STP Effluent	140-2200	Gomez et al., 2007
	Spain	Turia river	49	Carmona et al., 2014
	Spain	Mediterranean Sea	4	Gros et al., 2012
	Spain	Mediterranean Sea	nd-<LOQ	Rodriguez-Navas et al., 2013
	Singapore	Indian Ocean	<1.5-11.6	Bayen et al., 2013
	Singapore	Indian Ocean	4-38	Wu et al., 2010
Sweden	STP Effluent	700	Zorita et al., 2009	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	Sweden	STP Effluent	120	Bendz et al., 2005
	Sweden	Hospital Effluent	380	Zorita et al., 2009
	Switzerland	STP Effluent	1300-2400	Tauxe-Wuersch et al., 2005
	Taiwan	STP Effluent	4-101	Lin and Tsai, 2009
	Taiwan	Indian Ocean	<2.5-53.6	Fang et al., 2012
	United Kingdom	Rivers	<20-599	Ashton et al., 2004
	United Kingdom	Estuaries	<8-195	Thomas and Hilton 2004
	United Kingdom	North Sea	<0.12	Nebot et al., 2007
Ibuprofen	Canada	Detroit River	141	Metcalfe et al., 2003
	Canada	STP Effluent	110-2170	Lee et al., 2005
	China	Yellow River	41	Wang et al., 2010
	China	Hai River	75	Wang et al., 2010
	China	Liao River	7	Wang et al., 2010
	China	Pear River	78	Wang et al., 2010
	France	Mediterranean Sea	1500	Togola and Budzinki, 2008
	Germany	STP Effluent	370-3400	Ternes, 1998
	Italy	Po River	4-1000	Castiglioni et al., 2005 Zuccato et al., 2006
	Italy	Adriatic Sea	<0.049-1.146	Loos et al., 2013
	Luxembourg	STP Effluent	3-359	Pailler et al., 2009
	Norway	Norwegian Sea	<0.07-0.7	Weigel et al., 2004
	Portugal	Ave River	ND-362	Paiga et al., 2013
	Portugal	Aveiro Lagoon	242	Paiga et al., 2013
	Portugal	Douro River	ND-239	Paiga et al., 2013
	Portugal	Leça River	ND-265	Paiga et al., 2013
	Portugal	Lima River	42-739	Paiga et al., 2013
	Portugal	Minho River	204	Paiga et al., 2013
	Portugal	Tamega River	359	Paiga et al., 2013
	Portugal	Ulma River	173	Paiga et al., 2013
Portugal	Arade Estuary	28	Gonzalez Rey et al., 2015	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	Singapore	Indian Ocean	41-121	Wu et al., 2010
	Singapore	Seawater	<2.2-9.1	Bayen et al., 2013
	Spain	Rivers	25	Gros et al., 2006
	Spain	Drinking water	5	Gros et al., 2012
	Spain	STP Effluent	3812	Gros et al., 2012
	Spain	STP Effluent	240-28000	Gomez et al., 2007
	Spain	Turia river	830	Carmona et al., 2014
	Spain	Mediterranean Sea	16	Gros et al., 2012
	Sweden	Hospital Effluent	8800	Zorita et al., 2009
	Sweden	STP Effluent	150	Bendz et al., 2005
	Switzerland	Lake Greifenn	5,1	Buser et al., 1999
	Switzerland	Lake Baldegger	1.5-3.5	Buser et al., 1999
	Switzerland	Lake Pfaffiker	4	Buser et al., 1999
	Switzerland	Lake Zurich	3.3-4	Buser et al., 1999
	Switzerland	STP Effluent	81	Buser et al., 1999
	Switzerland	STP Effluent	100-1200	Taxe-Wuersch et al., 2005
	Taiwan	Indian Ocean	<2.5-57.1	Fang et al., 2012
	United Kingdom	Rivers	432-4201	Ashton et al., 2004
	United Kingdom	STP Effluent	1979-4239	Roberts and Bersuder, 2006
	United Kingdom	North Sea	<0.52	Nebot et al., 2007
	United Kingdom	Estuaries	<8-928	Thomas and Hilton 2004
Ketoprofen	Canada	STP Effluent	40-90	Lee et al., 2005
	France	Mediterranean Sea	6000	Togola and Budzinki, 2008
	Germany	STP Effluent	200-380	Ternes, 1998
	Japan	STP Effluent	68-219	Nakada et al., 2006
	Spain	STP Effluent	560	Gros et al., 2012
	Spain	STP Effluent	<LOQ-1760	Santos et al., 2005
	Spain	Mediterranean Sea	<8	Gros et al., 2012
	Sweden	STP Effluent	330	Bendz et al., 2005


	Taiwan	Indian Ocean	<1.7-6.59	Fang et al., 2012
	USA	STP Effluent	23	Thomas and Foster, 2004
Nimesulide	Ireland	STP Effluent	<LOQ-3500	Lacey et al., 2012
	Portugal	STP Effluent	<LOQ	Salgado et al.,2010
	Italy	Po river basin	nd-0.15	Ferrari et al., 2011

1
2
3
4
5
6
7
8
9
10
803
11
12
804
13
14
805
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

806 **Table 2.** Concentration of AMP, DIC, IBU, KET and NIM in *M. galloprovincialis* exposed to
 807 0.5µg/L for 14 days. Data are given in ng/g dry weight (mean values ± standard deviations, n=5).
 808 LOD= limit of detection (1 ng/g for AMP, 0.5 ng/g for IBU and KET)

		AMP	DIC	IBU	KET	NIM
Exposure	Control	<LOD	<LOD	<LOD	<LOD	<LOD
	Exposed	<LOD	4.75 ± 5.30	<LOD	<LOD	8.00 ± 3.99

812 **Table 3.** Quantitative Hazard Quotients (HQ) and assigned class of hazard after weighted
 813 elaboration of biomarker results in mussels exposed to AMP, DIC, IBU, KET and NIM.
 814

Treatment	HQ	Class of Hazard	Level
AMP	3.86	SLIGHT	
DIC	4.58	SLIGHT	
IBU	2.17	SLIGHT	
KET	18.69	MODERATE	
NIM	2.52	SLIGHT	

817 **Table 4.** Lists of the main biological processes modulated by KET and NIM exposures. The gene name of
818 differentially expressed transcripts are reported for each process and treatment. ↓ and ↑ indicate down- and
819 up-regulated genes.

	CTRL vs KET	CTRL vs NIM
METABOLISM		
<i>Glycolysis / Gluconeogenesis</i>	↓ <i>GAPDH</i> ; ↑ <i>PCK1, HK2, PCK2, PCXb</i>	↓ <i>PGMI, TPIIA, GAPDH, ADH5</i> ; ↑ <i>PCK1, PCK2, HK2</i>
<i>Citrate cycle (TCA cycle)</i>	↓ <i>IDH3G, SUCLG1</i> ; ↑ <i>PCK1, PCK2, PCXB</i>	↓ <i>IDH3G</i> ; ↑ <i>PCK1, PCK2</i>
<i>Oxidative phosphorylation</i>	↓ <i>NDUFS2, ATP5G3B, ATP6V1D, NDUFV2, NDUFA6, MT-ND4</i> ; ↑ <i>ATP6V1F, NDUFA8, MT-ND5</i>	↓ <i>COX4i1, NDUFA10, ATP6V1D, MT-CO1, ATP5G3, NDUFS2, NDUFV2, ATP6V0CB, ATP6V1E1B, ATP6V1H, NDUFA9</i> ; ↑ <i>MT-CO3</i>
<i>Glycerolipid metabolism</i>	↓ <i>PLRP1, AK1BA</i>	↓ <i>PLRP1, PPAP2A, GK2, AK1BA</i>
<i>Fatty acid metabolism</i>	↓ <i>RNPEP, SC5D, ACOX1</i> ; ↑ <i>ACAT1</i>	↓ <i>RNPEP, ACAA2, SC5D, TPIIA, ADH5</i>
<i>Drug metabolism</i>	↓ <i>XDH, TPMT</i> ; ↑ <i>GSTA4, SULT1B1, GSTP2, HSP70I</i>	↓ <i>GSTM, GSTP1, UCK2A, MGST3, CYP1A, SULT1ST1, CYP3A65</i> ; ↑ <i>HSP70L, GMPS, IMPDH2</i>
TRANSCRIPTION/TRANSLATION/FOLDING/DEGRADATION		
<i>Regulation of transcription</i>	↓ <i>BRF2, FOXG1A, ELF2A, HER6, TBX1, TAL1</i> ; ↑ <i>NR1D2A, TBX20, MED17, KAT6A, CNOT3B, MAX, BARHL1A, SUPT5H, NR2E3, NR0B1, SETD1BA, GTF2H3</i>	↓ <i>TRIM33, CFBF, LITAF, RARGB, CERS5, HER9, SUB1B, NR1D2B, HER6, FOSL1A</i> ; ↑ <i>SYNE1A, NR2E3, NR0B1, NFE2L2A, MAX, KDM2BA, SUPT5H, CHD4B</i>
<i>Spliceosome</i>	↓ <i>SNRPE</i> ; ↑ <i>RBM25, HSPA8, SNRNP70, NCBP2, PRPF40A</i>	↓ <i>TXNL4A, SNRPE, KCNF1B, SF3B14</i> ; ↑ <i>SF3B5, HSPA8, SNRNP70, PRPF40A, PUF60A, HNRNPM, CRNKL1</i>
<i>Translation/ Aminoacyl-tRNA biosynthesis</i>	↑ <i>FARSB, RPSA, RPLP0, EIF5, RPL30, RSL24D1, HSP90AB, NARS</i>	↓ <i>EEF1B2, EIF2S1B, RPL4</i> ; ↑ <i>FARSB, HARS, FARSA, RPLP2</i>
<i>Protein folding</i>	↑ <i>DNAJB1B, HSP90AA1.1, DNAJAI, CCT6A, DNAJB5, PFDN2, HSP70L, HSP70B2, HSC70</i>	↓ <i>TOR1L3</i> ; ↑ <i>PPIG, CLPX, DNAJB1B, HSP90AA1.1, DNAJA2, DNAJAI, CCT7, TCPI, HSP90AA1.2, HSP70B2, HSP70L</i>
<i>Proteolysis</i>	↓ <i>CTSC, RNPEP, ELA3L, PITRM1, STI1A, CTSL, CTSO, WWP2</i> ; ↑ <i>CUL1A, TCEB2, HERC1, VHLL, HUWE1, PIAS1B, UBE2L3A, CASP9</i>	↓ <i>RFWD2, WWP2, FBXW8, TRIM33, CTSC, CPVL, TLL1, CTSL, RNPEP, CTSL.1, PSMA2, CTSD, METAP1D, NAALAD2, UFSP2</i> ; ↑ <i>ADAM10A, PLG, BMP1A, BMP1B, HUWE1, TCEB1B, PIAS1B, TCEB2, SKP1</i>
<i>DNA repair</i>	↓ <i>BABAMI; GADD45AB</i> ↑ <i>ERCC2, RAD1, GTF2H3, SESN1</i>	↓ <i>MLH1</i> ; ↑ <i>RAD1, LIG1, PRP19, SESN1</i>

822 **Table 4.** continued

	CTRL vs KET	CTRL vs NIM
CELLULAR PROCESSES		
<i>Lysosome</i>	↓ <i>LAPTM4A, AP3S2, CTSC, CTSO, CTSL</i>	↓ <i>ATP6V1H, LAPTM4A, CTSL, CTSC, ATP6V0CB, CTSF, AP3S2, SLC17A5, CTSD, AP2B1, AP1S2, SMPD1, DNASE2B, AP5MI</i>
<i>Apoptosis</i>	↓ <i>GABARAP, CASP2, CASP3A, CASP7</i> ↑ <i>CASP9, BCL2L1, BIRC2, BAG4, RBM25, XIAP,</i>	↓ <i>GABARAP, CASP3A, CASP3B, APIP, CASP2;</i> ↑ <i>BAG4, BCL2L1, BIRC2, XIAP, BCL2</i>
<i>Cell cycle</i>	↓ <i>GADD45AB;</i> ↑ <i>HSP70L, CDK6, MCM7, CDC26, SESNI, NUSAPI, SESN3</i>	↓ <i>TXNL4A, MLH1;</i> ↑ <i>HSP70L, SKP1, MNAT1, KATNA1, NUSAPI, SESNI, CHAF1B, SESN3, MND1, MAPK7</i>
PPAR SIGNALING PATHWAY		
<i>PPAR signaling pathway</i>	↓ <i>DBI, ACOX1;</i> ↑ <i>UBB, PCK1, PCK2, LPINI</i>	↓ <i>GK2, DBI;</i> ↑ <i>PCK1, PCK2, UBC, LPINI</i>
IMMUNE SYSTEM		
<i>Immune response</i>	↓ <i>POLR3F, MGL</i> ↑ <i>HLEC, CLEC4F, CLEC4G, CLEC4M, TLR1, TLR2, TLR6, MARCO</i>	↓ <i>PGLYRP5, PGLYRP6, POLR3F, MGL</i> ↑ <i>ECSIT, TLR1, TLR3, CLEC4F, CLEC4G, RBL</i>
ARACHIDONIC ACID		
<i>Arachidonic acid metabolism</i>	↓ <i>TBXAS1, PGRI, PTGER4, RNPEPL1, CYP4</i> ↑ <i>PLA2</i>	↓ <i>TBXAS1, PGRI, PTGER4, RNPEPL1, CYP4</i> ↑ <i>PLA2</i>

Legends of Figures

Figure 1. Biomarker responses in control mussels (CTRL) and in those exposed to AMP, DIC, IBU, KET and NIM. NRRT: Neutral Red Retention Time; G/H: granulocytes-hyalinocytes ratio; percentage of phagocytosis; LIPO: lipofuscin; NL: neutral lipids; ACOX: Acyl-CoA oxidase; AChE; acetylcholinesterase. Results are given as mean values \pm standard deviations (n=5). Different letters indicate significant differences between groups of means (Newman-Keuls post hoc comparisons).

Figure 2. Antioxidant variations in control mussels (CTRL) and in those exposed to AMP, DIC, IBU, KET and NIM. CAT: catalase; GST: glutathione S-transferases; GPx H₂O₂ and GPx CHP: Se-dependent and sum of Se- dependent and Se-independent glutathione peroxidases; GR: glutathione reductase; GSH: levels of total glutathione; TOSC: total oxyradical scavenging capacity toward peroxy (ROO•) and hydroxyl (HO•). Results are given as mean values \pm standard deviations (n=5).

Figure 3. Biomarkers of genotoxic damage: percentage of DNA fragmentation and frequency of micronuclei (MN) in control mussels (CTRL) and in those exposed to AMP, DIC, IBU, KET and NIM. Results are given as mean values \pm standard deviations (n=5). Different letters indicate significant differences between groups of means (Newman-Keuls post hoc comparisons).

Figure 4. Principal Component Analysis (PCA) on biomarker data in control mussels (CTRL) and in those exposed to AMP, DIC, IBU, KET and NIM. Lipofuscin (LIPO), acetylcholinesterase activity (AChE), glutathione-S-transferases activity (GST), total glutathione (GSH), granulocytes-hyalinocytes ratio (G/H), catalase activity (CAT), Se-dependent and Se-independent glutathione peroxidases (GPx CHP), total Oxyradical Scavenging Capacity toward peroxy radicals (TOSC ROO•), micronuclei frequency (MN) and DNA fragmentation.

Figure 5. Venn diagrams representing differentially expressed transcripts (total, down-regulated and up-regulated) in the comparisons CTRL vs KET and CTRL vs NIM exposed mussels.

Figure 6. Principal Component Analysis (PCA) on transcriptional results in control mussels (CTRL) and in those exposed to KET and NIM. The analysis was performed considering the entire set of probes (6A); the 1,154 differentially expressed genes (DEGs) observed in KET exposed mussels (6B); the 1,516 DEGs observed in NIM exposed mussels (6C).

Figure(s)

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4






FIGURE 5

CTRL vs KET CTRL vs NIM




ALL DIFFERENTIALLY EXPRESSED GENES
(DEGs)

CTRL vs KET CTRL vs NIM




UPREGULATED GENES

CTRL vs KET CTRL vs NIM



DOWN REGULATED GENES

FIGURE 6



Supplementary Material 1

[Click here to download Supplementary Material: Supplementary Material 1.docx](#)

Supplementary Material 2

[Click here to download Supplementary Material: Supplementary Material 2.docx](#)

Supplementary Material 3

[Click here to download Supplementary Material: Supplementary Material 3.xlsx](#)

Supplementary Material 4

[Click here to download Supplementary Material: Supplementary Material 4.xlsx](#)

Supplementary Material 5

[Click here to download Supplementary Material: Supplementary Material 5.xlsx](#)

HIGHLIGHTS

Transcriptional and cellular effects of NSAIDs were investigated in mussels

Biological effects occurred even with limited or absent accumulation of NSAIDs

NSAIDs caused alterations of immune responses, lipid metabolism, DNA integrity

DNA microarrays revealed molecular pathways that supported biomarker results

Transcriptional changes were more sensitive exposure biomarkers than cellular effects